United Kingdom

Hikma continues strong momentum across the Group and upgrades guidance for 2023

Hikma continues strong momentum across the Group and upgrades guidance for 2023

AETOSWire sarjatha 2 November، 2023

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update...

Good momentum across all businesses and updated Generics guidance

Good momentum across all businesses and updated Generics guidance

AETOSWire sarjatha 29 April، 2023

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update...

Hikma strengthens US Injectables business through acquisition of Custopharm

Hikma strengthens US Injectables business through acquisition of Custopharm

Hikma strengthens US Injectables business through acquisition of Custopharm

AETOSWire sarjatha 12 April، 2023

Amman,Jordan, 12 April 2023 — Hikma Pharmaceuticals PLC (Hikma, Group), announces that Riad Mishlawi, President of the...

Collaboration between Al Hokair Group and IMPS to launch the first Smurfs FEC in the Mena region

Collaboration between Al Hokair Group and IMPS to launch the first Smurfs FEC in the Mena region

Collaboration between Al Hokair Group and IMPS to launch the first Smurfs FEC in the Mena region

AETOSWire sarjatha 19 October، 2022

ExCel London, United Kingdom — The recently concluded, Brand Licensing Europe tradeshow witnessed the signing of a license...

Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

AETOSWire sarjatha 18 July، 2022

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement...